Theralink Blog

Latest Blog Entries

Reflections on the American Association for Cancer Research (AACR) 2022 Annual Meeting

Recently, after 2 years of virtual conferences and online connections, Theralink had the chance to go to the 2022 American Association for Cancer Research (AACR) annual meeting in person. We caught up with our representatives Senior Research Specialist, Brian Corgiat, and Senior Director of Biopharma Commercial operations, Michael Fanelli. What was the main goal of … Continue reading Reflections on the American Association for Cancer Research (AACR) 2022 Annual Meeting

This or That: RPPA vs Mass Spectrometry vs ELISA

Previously, we discussed how proteomics is a better measure of the pharmacodynamic effects of target inhibition in drug development. There are a few ways to analyze protein levels and function across patients samples including Mass Spectrometry, ELISA, and our specialty, Reverse Phase Protein Array (RPPA). Today we’ll be giving an overview and comparison of a … Continue reading This or That: RPPA vs Mass Spectrometry vs ELISA

“Mitochondria is the Powerhouse of the Cell”

Mitochondria is the Powerhouse of the Cell. They are also involved in many signaling pathways including cell death, innate immunity, etc.

Theralink Enhanced Vehicles – CAR-T and CAR-NK

Chimeric Antigen Receptor (CAR) therapy is the modification of a patient’s immune cells so that they target cancer cells.  In the case of T-cells and CAR-T therapy, cells are taken from a patient’s blood and modified to include a special receptor (CAR receptor) that binds to a specific protein on the patient’s cancer cells. Scientists … Continue reading Theralink Enhanced Vehicles – CAR-T and CAR-NK

The Big 3: AKT-mTOR, Ras-MAPK, JAK-STAT

Today we will be diving into cross-talk between the Big 3 canonical pathways in cancer research: AKT-mTOR, Ras-MAPK, and JAK-STAT. Up to 70% of all human tumors have upregulated mTORC1 function and several oncogenes and/or tumor suppressors have been linked to mTOR signaling. Consequently, most cancer therapeutic strategies target mTOR signaling by way of AKT … Continue reading The Big 3: AKT-mTOR, Ras-MAPK, JAK-STAT

Into the I/O: A immuno-oncology PD1/PDL1 Case Study

Today let’s look into Immuno-oncology (I/O)- particularly using PD1/PDL1 as a case study! With several companies turning to I/O and immuno-therapy for cancer therapeutics, we offer several upstream and downstream targets of interest for patient stratification! One frequent question from our clients is that: “It’s a cool technology, but how can it benefit my PD-1/PD-L1 … Continue reading Into the I/O: A immuno-oncology PD1/PDL1 Case Study

The Theralink Assay

Theralink Technologies is a molecular profiling and precision medicine oncology company specializing in patented, biomarker assay services. We use quantitative Laser Capture Microdissection (LCM) and Reverse Phase Protein Array (RPPA) technology to support therapeutic development from discovery through clinical trials. This patented technology offers Next Generation Proteomics (NGP)TM services that produce in-depth broad-scale signalling analysis … Continue reading The Theralink Assay